The pattern of substance use disorder in the United Arab Emirates in 2015: Results of a National Rehabilitation Centre cohort study

Substance Abuse: Treatment, Prevention, and Policy

Volumn 11, Issue 1, 2016, Pages

  Alblooshi, Hiba ^a   Hulse, Gary K ^a   El Kashef, Ahmed ^b   Al Hashmi, Hanan ^b   Shawky, Mansour ^b   Al Ghaferi, Hamad ^b   Al Safar, Habiba ^c   Tay, Guan K ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b United Arab Emirates National Rehabilitation Center   (United Arab Emirates)

^c KHALIFA UNIVERSITY   (United Arab Emirates)

Author keywords

Alcohol drinking; Opioid related disorders; Prescription medication use; Substance related disorders; United Arab Emirates

Indexed keywords

ADOLESCENT; ADULT; AGE; COHORT ANALYSIS; DRUG MISUSE; HUMAN; MALE; MIDDLE AGED; RISK FACTOR; STATISTICS AND NUMERICAL DATA; SUBSTANCE-RELATED DISORDERS; UNITED ARAB EMIRATES; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; COHORT STUDIES; HUMANS; MALE; MIDDLE AGED; PRESCRIPTION DRUG MISUSE; RISK FACTORS; SUBSTANCE-RELATED DISORDERS; UNITED ARAB EMIRATES; YOUNG ADULT;

EID: 84971273022     PISSN: None     EISSN: 1747597X     Source Type: Journal    
DOI: 10.1186/s13011-016-0062-5     Document Type: Article

References (44)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-5. 2013.
2. Connor JP, Gullo MJ, White A, Kelly AB. Polysubstance use: diagnostic challenges, patterns of use and health. Curr Opin Psychiatry. 2014;27(4):269-75.
3. Deborah SH, Charles POB, Marc A, Guilherme B, Kathleen B, Alan B, et al. DSM-5 criteria for substance use disorders: recommendations and rationale. Am J Psychiatr. 2013;170(8):834-51.
4. Sweileh W, Sweileh S, Zyoud S, Al Jabi A. Substance use disorders in Arab countries: research activity and bibliometric analysis. Subst Abuse Treat Prev Policy. 2014;9(1):33.
5. AlMarri T, Oeii TPS. Alcohol and substance use in the Arabian Gulf region: a review. Int J Psychol. 2009;44(3):222-33.
6. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2014. United Nations publication; 2014.
7. AbuMadini MS, Rahim SIA, Al-Zahrani MA, Al-Johi AO. Two decades of treatment seeking for substance use disorders in Saudi Arabia: trends and patterns in a rehabilitation facility in Dammam. Drug Alcohol Depend. 2008;97(3):231-6.
8. Amir T. Comparison of patterns of substance abuse in Saudi Arabia and The United Arab Emirates. Soc Behav Personal. 2001;29(6):519.
9. Younis YO, Saad AG. A profile of alcohol and drug misusers in an Arab community. Addiction. 1995;90(12):1683-4.
10. Elarabi H, Al Hamedi F, Salas S, Wanigaratne S. Rapid analysis of knowledge, attitudes and practices towards substance addiction across different target groups in Abu Dhabi City, United Arab Emirates. Int J Prev Treat Subst Use Disord. 2013;1(1):76-88.
11. Elkashef A, Zoubeidi T, Thomas RA, Al Hashmi H, Lee AJ, Aw T-C, et al. A profile of patients with substance use disorders and treatment outcomes: a 10-year retrospective study from the National Rehabilitation Center. Int J Prev Treat Subst Use Disord. 2013;1(1):62-75.
12. Alsafar H, Jama-Alol K, Hassoun AK, Tay G. The prevalence of type 2 diabetes mellitus in the United Arab Emirates: justification for the establishment of the Emirates family registry. Int J Diab Dev Ctries. 2012;32(1):25-32.
13. World medical association declaration of helsinki. Recommendations guiding physicians in biomedical research involving human subjects. J Am Med Assoc. 1997;277(11):925-6.
14. Faul F, Erdfelder E, Lang A-G, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39:175-91.
15. Liu X, Weiss F. Additive effect of stress and drug cues on reinstatement of ethanol seeking: exacerbation by history of dependence and role of concurrent activation of corticotropin-releasing factor and opioid mechanisms. J Neurosci. 2002;22(18):7856-61.
16. Al-Harthi A, Al-Adawi S. Enemy within? The silent epidemic of substance dependency in GCC countries. SQU J Sci Res Med Sci. 2002;4(1-2):1-7.
17. Uhl GR. Molecular genetic underpinnings of human substance abuse vulnerability: likely contributions to understanding addiction as a mnemonic process. Neuropharmacology. 2004;47:140-7.
18. Hodgkinson CA, Yuan Q, Xu K, Shen PH, Heinz E, Lobos EA, et al. Addictions biology: haplotype-based analysis for 130 candidate genes on a single array. Alcohol Alcohol. 2008;43(5):505-15.
19. Ball D. Addiction science and its genetics. Addiction. 2008;103(3):360-7.
20. Bassiony M. Substance use disorders in Saudi Arabia: review article. J Subst Use. 2013;18(6):450-66.
21. Darke S. Oxycodone poisoning: not just the 'usual suspects'. Addiction. 2011;106(6):1035-6.
22. Degenhardt L, Charlson F, Mathers B, Hall WD, Flaxman AD, Johns N, et al. The global epidemiology and burden of opioid dependence: results from the global burden of disease 2010 study. Addiction. 2014;109(8):1320-33.
23. Compton WM, Volkow ND. Abuse of prescription drugs and the risk of addiction. Drug Alcohol Depend. 2006;83:S4-7.
24. McCabe SE, Cranford JA, West BT. Trends in prescription drug abuse and dependence, co-occurrence with other substance use disorders, and treatment utilization: results from two national surveys. Addict Behav. 2008;33(10):1297-305.
25. LeClair A, Kelly BC, Pawson M, Wells BE, Parsons JT. Motivations for prescription drug misuse among young adults: considering social and developmental contexts. Drugs (Abingdon England). 2015;22(3):208-16.
26. Copeland J, Swift W. Cannabis use disorder: epidemiology and management. Int Rev Psychiatry. 2009;21(2):96-103.
27. Fergusson D, Boden J, Horwood LJ. Psychosocial sequelae of cannabis use and implications for policy: findings from the Christchurch Health and Development Study. Soc Psychiatry Psychiatr Epidemiol. 2015;50(9):1317-26.
28. Morley KI, Lynskey MT, Moran P, Borschmann R, Winstock AR. Polysubstance use, mental health and high-risk behaviours: results from the 2012 Global Drug Survey. Drug Alcohol Rev. 2015;34(4):427-37.
29. Beakley BD, Kaye AM, Kaye AD. Tramadol, pharmacology, side effects, and serotonin syndrome: a review. Pain Physician. 2015;18(4):395-400.
30. Gameel TA, Tawfik AM, Abou-Farha MO, Bastawisy MG, El-Bendary MA, El-Gamasy AE-N. On-demand use of tramadol, sildenafil, paroxetine and local anaesthetics for the management of premature ejaculation: a randomised placebo-controlled clinical trial. Arab J Urol. 2013;11(4):392-7.
31. Ryan NM, Isbister GK. Tramadol overdose causes seizures and respiratory depression but serotonin toxicity appears unlikely. Clin Toxicol. 2015;53(6):545-50.
32. Bush DM. Emergency Department Visits for Drug Misuse or Abuse Involving the Pain Medication Tramadol. The CBHSQ Report. Rockville: Substance Abuse and Mental Health Services Administration (US); 2013.
33. Compton WM, Volkow ND. Major increases in opioid analgesic abuse in the United States: concerns and strategies. Drug Alcohol Depend. 2006;81(2):103-7.
34. McCabe SE, Schulenberg JE, O'Malley PM, Patrick ME, Kloska DD. Non-medical use of prescription opioids during the transition to adulthood: a multi-cohort national longitudinal study. Addiction. 2014;109(1):102-10.
35. Martinotti G. Pregabalin in clinical psychiatry and addiction: pros and cons. Expert Opin Investig Drugs. 2012;21(9):1243-5.
36. Loftus H, Wright A. Potential misuse of pregabalin and gabapentin. Br Med J. 2014;348:g1290.
37. Schwan S, Sundstrom A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin--results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66(9):947-53.
38. Pullen GP, Best NR, Maguire J. Anticholinergic drug abuse: a common problem? Br Med J. 1984;289(6445):612-3.
39. Dooris B, Reid C. Feigning dystonia to feed an unusual drug addiction. J Accid Emerg Med. 2000;17(4):311.
40. Buhrich N, Weller A, Kevans P. Misuse of anticholinergic drugs by people with serious mental illness. Psychiatr Serv. 2000;51(7):928-9.
41. Gatch MB, Nguyen JD, Carbonaro T, Forster MJ. Carisoprodol tolerance and precipitated withdrawal. Drug Alcohol Depend. 2012;123(1-3):29-34.
42. Reeve R, Burke R. Carisoprodol: abuse potential and withdrawal syndrome. Curr Drug Abuse Rev. 2010;3(1):33-8.
43. Alam-Mehrjerdi Z, Abdollahi M, Higgs P, Dolan K. Drug use treatment and harm reduction programs in Iran: a unique model of health in the most populated Persian Gulf country. Asian J Psychiatry. 2015;16:78-83.
44. Alam-mehrjerdi Z, Mokri A, Dolan K. Methamphetamine use and treatment in Iran: a systematic review from the most populated Persian Gulf country. Asian J Psychiatry. 2015;16:17-25.